ARS Pharmaceuticals (SPRY) Cash from Investing Activities Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ARS Pharmaceuticals | 576.91 Mn | 375.94 Mn | - | -4.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.38% |
| Dec 31, 2025 | 123.70% |
| Sep 30, 2025 | -367.46% |
| Jun 30, 2025 | 484.08% |
| Mar 31, 2025 | 441.41% |
| Dec 31, 2024 | -490.80% |
| Sep 30, 2024 | 136.06% |
| Jun 30, 2024 | -128.12% |
| Mar 31, 2024 | 92.37% |
| Dec 31, 2023 | 20,765.87% |
| Sep 30, 2023 | -155,376.67% |
| Jun 30, 2023 | 204,509.09% |
| Mar 31, 2023 | -531,071.43% |
| Dec 31, 2022 | -100.31% |
| Sep 30, 2022 | 99.93% |
| Jun 30, 2022 | 96.86% |
| Mar 31, 2022 | 40.00% |
| Dec 31, 2021 | 16,593.12% |
| Sep 30, 2021 | -6,238.29% |
| Jun 30, 2021 | -13,900.00% |